microRNAs and oligometastasis

Khodarev, Nikolai N.; Pitroda, Sean P.; Weichselbaum, Ralph R.

doi:10.18632/aging.100731

Cited by 8 publications

(4 citation statements)

References 7 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These benchmarks may include circulating tumor cells, cell-free DNA/RNA, and micro-RNA (20)(21)(22). Studies have suggested that oligometastases may be less genomically heterogeneous than polymetastatic disease manifested by different micro-RNA profiles (23,24). However, other studies have failed to delineate a serum-derived micro-RNA signature that can discriminate between oligometastatic and polymetastatic disease (25).…”

Section: Biologic Basismentioning

confidence: 99%

Oligometastatic Prostate Cancer: Current Status and Future Challenges

et al. 2022

View full text Add to dashboard Buy / Rent full text

Learning Objectives: On successful completion of this activity, participants should be able to (1) describe the clinical state of oligometastatic disease along the natural history of prostate cancer; (2) discuss the outcome results of the various clinical trials on metastasis-directed therapy of oligometastatic disease in prostate cancer; and (3) recognize the gaps in knowledge and needed additional areas of research relevant to oligometastatic prostate cancer.

show abstract

Section: Biologic Basismentioning

confidence: 99%

Oligometastatic Prostate Cancer: Current Status and Future Challenges

et al. 2022

View full text Add to dashboard Buy / Rent full text

show abstract

“…A number of molecular markers have been proposed to play a significant role in the differentiation between oligometastatic and polymetastatic disease. For example, analysis of microRNA expression in cancer patients has allowed the identification of potential "oligomiRs" that could help identify oligometastatic phenotypes (17). In a study performed by Lussier et al, the authors analyzed patterns of microRNA expression in tumor samples from patients with oligometastatic disease that were treated with high-dose RT.…”

Section: Definition Of Oligometastatic Diseasementioning

confidence: 99%

The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review

Berzenji¹,

Debaenst

Hendriks

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Buy / Rent full text

In this review, we aim to summarize the most recent data on the surgical management of oligometastatic non-small cell lung cancer (NSCLC).Background: Approximately 60-70% of all patients with NSCLC initially present with advanced stages of cancer at time of diagnosis. These patients are generally treated with chemotherapy, radiation therapy, or a combination of these modalities. Patients with late-stage disease are usually not considered to be amenable for curative-intent treatments due to poor prognoses. Despite advances in systemic therapies, 5-year overall survival rates in these patients remain poor. However, technological advances in imaging modalities and new imaging strategies have substantially increased tumor detection rates and have resulted in a shift towards earlier diagnosis of NSCLC, possibly in stages in which metastatic disease is limited and still treatable.Studies in recent years have shown that there is a distinct group of patients with metastatic lesions at one or a few sites, often referred to as oligometastatic disease, that may have better survival outcomes compared to patients with more disseminated diseases. Furthermore, it is suggested that these patients may benefit from a combination of systemic treatment and local treatment aimed at the metastatic site(s). However, the role of surgery in this setting remains a controversial subject, with many unanswered questions.Methods: The PubMed/MEDLINE database and the Cochrane database were searched to find relevant articles regarding oligometastatic NSCLC. Specifically, articles regarding definitions of oligometastatic disease, oligometastatic tumor biology, diagnosis, and the treatment of oligometastatic disease were identified.Conclusions: Oligometastatic NSCLC represents a wide spectrum of diseases and encompasses a heterogeneous patient population. Current data suggests that local ablative treatment of oligometastatic lesions with surgery or stereotactic body radiation therapy may result in improved overall survival and progression-free survival rates. However, more data from multi-center prospective trials are necessary to shed light on which therapeutic modalities are most suitable for the treatment of oligometastatic NSCLC.Integration of clinical and molecular staging data is necessary to allow for more personalized treatment approaches.

show abstract

“…These microRNAs were defined as "oligomiRs". Among them, one common locus at 14q32 associated with carcinogenesis and stem cell functioning, encoded for a significant number of oligomiRs (115).…”

Section: Tme In Oligometastatic and Oligoprogressive Cancers Including Nsclcmentioning

confidence: 99%

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done

Belluomini

Dodi

Caldart

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Buy / Rent full text

In this review, we aim to collect and discuss available data about the role and composition of tumor microenvironment (TME) in oligometastatic (OMD) and oligoprogressive (OPD) non-small cell lung cancer (NSCLC). Furthermore, we aim to summarize the ongoing clinical trials evaluating as exploratory objective the TME composition, through tissue and/or blood samples, in order to clarify whether TME and its components could explain, at least partially, the oligometastatic/oligoprogressive process and could unravel the existence of predictive and/or prognostic factors for local ablative therapy (LAT).Background: OMD/OPD NSCLC represent a heterogeneous group of diseases. Several data have shown that TME plays an important role in tumor progression and therefore in treatment response. The crucial role of several types of cells and molecules such as immune cells, cytokines, integrins, protease and adhesion molecules, tumor-associated macrophages (TAMs) and mesenchymal stem cells (MSCs) has been widely established. Due to the peculiar activation of specific pathways and expression of adhesion molecules, metastatic cells seem to show a tropism for specific anatomic sites (the so-called "seed and soil" hypothesis).Based on this theory, metastases appear as a biologically driven process rather than a random release of cancer cells. Although the role and the function of TME at the time of progression in patients with NSCLC treated with tyrosine-kinase inhibitors and immune checkpoint inhibitors (ICIs) have been investigated, limited data about the role and the biological meaning of TME are available in the specific OMD/OPD setting.Methods: Through a comprehensive PubMed and ClinicalTrials.gov search, we identified available and ongoing studies exploring the role of TME in oligometastatic/oligoprogressive NSCLC.Conclusions: Deepening the knowledge on TME composition and function in OMD/OPD may provide innovative implications in terms of both prognosis and prediction of outcome in particular from local treatments, paving the way for future investigations of personalized approaches in both advanced and early

show abstract

microRNAs and oligometastasis

Cited by 8 publications

References 7 publications

Oligometastatic Prostate Cancer: Current Status and Future Challenges

Oligometastatic Prostate Cancer: Current Status and Future Challenges

The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done

Contact Info

Product

Resources

About